Company News
New CRISPR/Cas9 license agreement to advance disease model development
May 31 2024
Ricoh Company, Ltd has announced a non-exclusive licensing agreement with ERS Genomics Ltd for access to foundational CRISPR/Cas9 genome editing technology patents in the USA and Japan.
CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise modification of targeted genome sequences. It plays a crucial role in drug discovery and is utilised in various research fields.
In 2022, Ricoh acquired Elixirgen Scientific, Inc, which specialises in rapid and efficient differentiation of human iPS cells and mRNA design, production, and management. Combining these technologies with CRISPR/Cas9, Ricoh aims to enhance the prediction of drug mechanisms for patients with diverse genetic backgrounds and to improve mRNA design speed and efficiency. This integration allows for the creation of reliable disease models, including those for rare diseases, potentially shortening drug development timelines and increasing success rates.
Ricoh is expanding the application of Elixirgen Scientific's technology by utilising its expertise in digital and artificial intelligence technologies. This initiative aims to accelerate personalised medicine, drug discovery research, and regenerative medicine. Ricoh is committed to advancing drug development research through the diverse solutions offered by Elixirgen Scientific.
Summit Pharmaceuticals International Corporation, a subsidiary of Sumitomo Corporation, is the exclusive representative of ERS Genomics in Japan.
More information online
Digital Edition
International Labmate Buyers' Guide 2024/25
June 2024
Buyers' Guide featuring: Product Listings & Manufacturers Directory Chromatography Articles - Enhancing HPLC Field Service with fast-response, non-invasive flowmeters - Digital transformatio...
View all digital editions
Events
Jul 07 2024 Dublin, Ireland
Jul 20 2024 Denver, CO, USA
Jul 21 2024 Cape Town, South Africa
Jul 28 2024 San Diego, CA USA
Jul 30 2024 Jakarta, Indonesia